Wednesday, November 19, 2025
4:00 PM -
5:00 PM
Gates Annex B122
Peter B. Dervan Lecture
Series: Peter B. Dervan Lecture Series
I. Adding New Chemistries to the Central Dogma; II. A New Vision for Nonprofit Research
Peter G. Schultz,
CEO and President,
L.S. "Sam" Skaggs Presidential Chair Department of Chemistry,
Scripps Research Institute,
Speaker's Bio:
Peter G. Schultz did his undergraduate and graduate work at the California Institute of Technology. In 1985, after postdoctoral studies at the Massachusetts Institute of Technology, he joined the faculty of the University of California at Berkeley, where he was Professor of Chemistry, Principal Investigator at Lawrence Berkeley National Laboratory and an Investigator of the Howard Hughes Medical Institute. Schultz joined the faculty of Scripps in 1999 where he is currently the Scripps Family Professor of Chemistry and President of Scripps. He founded and was the Institute Director of the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, CA from 1999 to 2010 and more recently (2012) the California Institute for Biomedical Research (CALIBR), a not-for-profit institute focused on early stage translational research. In addition, Schultz is a founder of Affymax Research Institute, Syrrx, Kalypsys, Phenomix, Symyx Therapeutics, Ilypsa, Ambrx, Ardelyx, and Wildcat Technologies, pioneers in the application of diversity based approaches to problems in chemistry, materials science and medicine. His awards include the Waterman Award of the National Science Foundation, membership in the National Academy of Sciences and National Institute of Medicine, the Wolf Prize in Chemistry, the Paul Ehrlich Prize, the Arthur C. Cope Award of the American Chemical Society, the Solvay Prize, and Wieland Prize. He has co-authored 600 scientific publications and trained over 300 graduate students and postdoctoral fellows, many of whom are on the faculties of major research institutions around the world.
Peter G. Schultz did his undergraduate and graduate work at the California Institute of Technology. In 1985, after postdoctoral studies at the Massachusetts Institute of Technology, he joined the faculty of the University of California at Berkeley, where he was Professor of Chemistry, Principal Investigator at Lawrence Berkeley National Laboratory and an Investigator of the Howard Hughes Medical Institute. Schultz joined the faculty of Scripps in 1999 where he is currently the Scripps Family Professor of Chemistry and President of Scripps. He founded and was the Institute Director of the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, CA from 1999 to 2010 and more recently (2012) the California Institute for Biomedical Research (CALIBR), a not-for-profit institute focused on early stage translational research. In addition, Schultz is a founder of Affymax Research Institute, Syrrx, Kalypsys, Phenomix, Symyx Therapeutics, Ilypsa, Ambrx, Ardelyx, and Wildcat Technologies, pioneers in the application of diversity based approaches to problems in chemistry, materials science and medicine. His awards include the Waterman Award of the National Science Foundation, membership in the National Academy of Sciences and National Institute of Medicine, the Wolf Prize in Chemistry, the Paul Ehrlich Prize, the Arthur C. Cope Award of the American Chemical Society, the Solvay Prize, and Wieland Prize. He has co-authored 600 scientific publications and trained over 300 graduate students and postdoctoral fellows, many of whom are on the faculties of major research institutions around the world.
Ongoing efforts will be described that add new amino acids to the genetic code and their application as biological tools and new therapeutics. II. A new institutional model being developed at Scripps will be overviewed- one that bridges basic and translational research to accelerate the development of new medicines and which, as a consequence, provides a sustainable source of future scientific funding.
Event Sponsors:
For more information, please contact Julianne Just by phone at x2924 or by email at [email protected].
